Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2021

View Archived Issues

Positive phase II data published from GENETIC-AF study of bucindolol in patients with heart failure

Syros enters clinical supply agreement with Roche to evaluate SY-5609 as part of INTRINSIC study

Enanta nominates EDP-235 as clinical candidate for the treatment of COVID-19

Suzhou Zelgen Biosciences discovers G12C mutant GTPase KRAS inhibitors

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent cereblon ligands

Hisun Accuray Therapeutics, Zhejiang Hisun Pharmaceutical present SHP-2 inhibitors

New thyroid hormone receptor agonists divulged by Eccogene

Aptahem reports positive preliminary results from GLP studies of Apta-1

Enrollment begins in phase II study of Stemedica's itMSCs in patients with COVID-19

Exicure provides updated interim data from phase Ib/II study of cavrotolimod

INPP5D inhibition reduces amyloid pathology in Alzheimer's disease model

First patient dosed in IMP-MEL study of PORT-2 for the treatment of melanoma and NSCLC

Clene provides topline data from REPAIR-PD and REPAIR-MS studies

MYMD-1 shows the ability to suppress cytokine storm in human cells

Nullifying necrosis: unfolded protein response inhibitors fight flesh-eating bacteria

Dosing begins in phase II portion of phase I/II trial of AKS-452

FDA places partial clinical hold on Aprea's myeloid malignancy programs

Enrollment starts in phase I study of ZYIL-1

Boehringer Ingelheim initiates phase I/II study of BI-765128 in diabetic macular ischemia

Labile iron pool radiotracer [18F]TRX can predict sensitivity to iron-targeted tumor therapies

GI Innovation begins patient enrollment in phase I/II study of GI-101

Enrollment ongoing in first-in-human study of [68Ga]-FF58

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...